Russia amps up spending on locally made meds to spur Big Pharma production

Russia has a lot of purchasing muscle, but few local producers when it comes to pharmaceuticals, and so officials have cooked up a plan to lure more foreign pharma partners. The government will boost its spending on locally made drugs, hoping to inspire Big Pharma to set up production in the country. More from FiercePharmaAsia

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.